Opinion: The Warren bill could promote beneficial public-private partnerships in life sciences
Public-private partnerships will gather momentum in 2019. Life sciences companies should make them a bigger part of their portfolios.
Bills like the Affordable Drug Manufacturing Act, if enacted, could help a beneficial trend gather momentum in 2019: life sciences companies making public-private partnerships a bigger focus of their business strategies.
The bill, proposed by Sen. Elizabeth Warren (D-Mass.) and Rep. Jan Schakowsky (D-Ill.), would create an Office of Drug Manufacturing aimed at boosting competition, lowering drug prices, and addressing prescription drug shortages, among other goals.
The office would have the power to manufacture new generic drugs or enter into contracts with other entities to make them when there’s a drug shortage or when.
